Research funds pay off with mortality decline

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

The cancer death rate continues to decline, according to the latest report, and at an even faster rate than previously. Cancer mortality decreased by 2.1% per year from 2002 to 2004, almost double the 1.1% decline seen each year from 1993 to 2002.

The cancer death rate continues to decline, according to the latest report, and at an even faster rate than previously. Cancer mortality decreased by 2.1% per year from 2002 to 2004, almost double the 1.1% decline seen each year from 1993 to 2002.

The Annual Report to the Nation, produced by NCI, CDC, the American Cancer Society, and the North American Association of Central Cancer Registries, was published in Cancer (110:2119-2152, 2007), following advance online release.

The biggest contributor to the decline was the fall in colorectal cancer deaths in both men and women, the authors said. Such deaths dropped by 4.9% a year in men and 4.5% in women, due in part to advances in treatment, and new diagnoses of colorectal cancer were down 2.8% in men and 2.4% in women, probably due to colorectal screening.

ASCO president Nancy E. Davidson, MD, attributed the findings to the national investment in cancer research. "These exciting new data demonstrate what many of us in the cancer research and practice community have known for some time. The long-term federal investment in cancer research is paying off," she said, adding that "this impressive pace of progress will slow if we don't recommit to funding cancer research."

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content